报价延迟最少15分钟:2026/04/26 04:11 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.64 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.84/-0.06
|
|
企业价值
318.62M
|
| 资产负债 |
|
每股账面净值
-0.55
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
45.15M
|
|
每股收益
0.21
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9)agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav. |
